

# PRODUCT SPECIFICATION

STATENS  
SERUM  
INSTITUT



## CMA 001 HybER™ Hybridoma Enhancing Reagent

*Culture Medium Additive*

*Lyophilized*

<b>Article No.</b>	64715												
<b>Product Name</b>	CMA 001 HybER™ Hybridoma Enhancing Reagent												
<b>Presentation</b>	<b>Appearance:</b> Clear light yellow, orange or pink solution. <b>Content:</b> 2.5 mL, lyophilized												
<b>Storage</b>	<b>Lyophilized:</b> at room temperature <b>Solution:</b> at -18°C or colder for long-term storage at 2-8°C when in use												
<b>Expiry</b>	<b>Lyophilized:</b> Exp.date <b>Solvent:</b> Exp.date at -18°C or colder 6 months after reconstitution at 2-8°C												
<b>Sterility</b>	<b>Sterility:</b> Non-sterile <b>Packaging:</b> Lyophilized and sealed under aseptic conditions <b>Mycoplasma:</b> Negative in PCR screening <b>Endotoxin:</b> Negative in LAL-test												
<b>Description</b>	HybER™ stimulates growth of mouse hybridomas immediately after fusion and during cloning procedures (1,2). HybER™ contains small amounts of Foetal Bovine Serum from certified BSE-free suppliers.												
<b>Protocol of use</b>	To prepare HybER™ for laboratory use: 1) Reconstitute with 2.5 mL water for injection (WFI) or culture medium directly into the vial with lyophilized HybER™. 2) Solubilise all material by pipetting gently up and down. 3) Filtrate the reconstituted HybER™ through a 0.22 µm sterile filter.  HybER™ is now ready for use and suitable amounts can be added as needed to the standard growth medium during fusions and clonings.												
<b>Dilution Guide</b>	We recommend using HybER™ at a dilution of 0.5% (v/v) in growth medium immediately after fusion, at the first medium change after fusion, and during subsequent cloning steps. At our recommended dilution, one vial of HybER™ (2.5 mL) is sufficient to supply 500 mL of growth medium.												
<b>Application</b>	<table border="1"><thead><tr><th>Method</th><th>Usability</th><th>Dilution guide</th></tr></thead><tbody><tr><td>Fusion</td><td>yes</td><td>0.5% (v/v)</td></tr><tr><td>Cloning</td><td>yes</td><td>0.5% (v/v)</td></tr><tr><td>Production</td><td>nd.</td><td>nd.</td></tr></tbody></table>	Method	Usability	Dilution guide	Fusion	yes	0.5% (v/v)	Cloning	yes	0.5% (v/v)	Production	nd.	nd.
Method	Usability	Dilution guide											
Fusion	yes	0.5% (v/v)											
Cloning	yes	0.5% (v/v)											
Production	nd.	nd.											
<b>References</b>	<ol style="list-style-type: none"><li>1. <b>Trier NH, Mortensen A, Schiølborg A, Friis T.</b> Production and Screening of Monoclonal Peptide Antibodies. <i>Methods Mol Biol.</i> 2015;1348:109-26.</li><li>2. <b>Schwelberger HG, Feurle J, Houen G.</b> New tools for studying old questions: antibodies for human diamine oxidase. <i>J Neural Transm.</i> 2013;120:1019-1026.</li></ol>												

### Conditions

For research use only. Not for use in diagnostic procedures. Not for therapeutic use or applications.

The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall Statens Serum Institut be responsible for loss of profits or indirect consequential losses resulting from use of its products. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.